PsymaTalk: Our Take on ASCO 2018 - Part 1

with Gordon Gochenauer, Oncology lead at Psyma USA

Gordon Gochenauer, shares his takeaways from ASCO 2018 in a podcast miniseries.

In this Part 1, Array Biopharma’s RAF/MEK combination, encorafenib and binimetinib, nicknamed COMBO450, posted a median overall survival of 33 months in BRAF-mutated melanoma in the COLUMBUS trial.  This new combination, likely to be approved by the end of June 2018, may be well-positioned to challenge Genentech/Roche’s and Novartis’ respective RAF/MEK combinations which have not surpassed 30 months in OS in trials.

 

Contact us to find out more about our Oncology Practice.

 

Psyma Group AG

Rueckersdorf/Nuremberg Germany
Phone: +49 (0)911 99574-0
E-Mail: info@psyma.com